U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Locally Advanced Midgut Neuroendocrine Tumor

MedGen UID:
1714216
•Concept ID:
C5238466
•
Neoplastic Process

Definition

A midgut neuroendocrine tumor that has spread from its original site of growth to nearby tissues or lymph nodes. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVLocally Advanced Midgut Neuroendocrine Tumor

Professional guidelines

PubMed

ASO Practice Guidelines Series: Surgical Management of Gastrointestinal (Midgut) Neuroendocrine Neoplasms.
Hallet J, Clarke CN
Ann Surg Oncol 2024 Mar;31(3):1704-1713. Epub 2024 Jan 2 doi: 10.1245/s10434-023-14802-8. PMID: 38167813
Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms.
Alexandraki KI, Karapanagioti A, Karoumpalis I, Boutzios G, Kaltsas GA
Biomed Res Int 2017;2017:9856140. Epub 2017 Nov 19 doi: 10.1155/2017/9856140. PMID: 29349087Free PMC Article
Management of neuroendocrine tumors.
Chung C
Am J Health Syst Pharm 2016 Nov 1;73(21):1729-1744. doi: 10.2146/ajhp150373. PMID: 27769969

Recent clinical studies

Etiology

ASO Practice Guidelines Series: Surgical Management of Gastrointestinal (Midgut) Neuroendocrine Neoplasms.
Hallet J, Clarke CN
Ann Surg Oncol 2024 Mar;31(3):1704-1713. Epub 2024 Jan 2 doi: 10.1245/s10434-023-14802-8. PMID: 38167813
(177)Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators
Lancet Oncol 2021 Dec;22(12):1752-1763. Epub 2021 Nov 15 doi: 10.1016/S1470-2045(21)00572-6. PMID: 34793718
Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results.
Pavel M, Ćwikła JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Capdevila J, Panzuto F, Truong Thanh XM, Houchard A, Ruszniewski P
Eur J Cancer 2021 Nov;157:403-414. Epub 2021 Sep 28 doi: 10.1016/j.ejca.2021.06.056. PMID: 34597974
Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms.
Alexandraki KI, Karapanagioti A, Karoumpalis I, Boutzios G, Kaltsas GA
Biomed Res Int 2017;2017:9856140. Epub 2017 Nov 19 doi: 10.1155/2017/9856140. PMID: 29349087Free PMC Article
The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum.
Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, Nutting C, Bushnell DL, Caplin ME, Yao JC; North American Neuroendocrine Tumor Society (NANETS)
Pancreas 2010 Aug;39(6):753-66. doi: 10.1097/MPA.0b013e3181ebb2a5. PMID: 20664473

Diagnosis

Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms.
Alexandraki KI, Karapanagioti A, Karoumpalis I, Boutzios G, Kaltsas GA
Biomed Res Int 2017;2017:9856140. Epub 2017 Nov 19 doi: 10.1155/2017/9856140. PMID: 29349087Free PMC Article
Management of neuroendocrine tumors.
Chung C
Am J Health Syst Pharm 2016 Nov 1;73(21):1729-1744. doi: 10.2146/ajhp150373. PMID: 27769969
Pancreatic neoplasm in 2011: an update.
Saif MW
JOP 2011 Jul 8;12(4):316-21. PMID: 21737886
The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum.
Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, Nutting C, Bushnell DL, Caplin ME, Yao JC; North American Neuroendocrine Tumor Society (NANETS)
Pancreas 2010 Aug;39(6):753-66. doi: 10.1097/MPA.0b013e3181ebb2a5. PMID: 20664473
Chemotherapy for gastro-enteropancreatic endocrine tumours.
O'Toole D, Hentic O, Corcos O, Ruszniewski P
Neuroendocrinology 2004;80 Suppl 1:79-84. doi: 10.1159/000080747. PMID: 15477723

Therapy

(177)Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators
Lancet Oncol 2021 Dec;22(12):1752-1763. Epub 2021 Nov 15 doi: 10.1016/S1470-2045(21)00572-6. PMID: 34793718
Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results.
Pavel M, Ćwikła JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Capdevila J, Panzuto F, Truong Thanh XM, Houchard A, Ruszniewski P
Eur J Cancer 2021 Nov;157:403-414. Epub 2021 Sep 28 doi: 10.1016/j.ejca.2021.06.056. PMID: 34597974
Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms.
Alexandraki KI, Karapanagioti A, Karoumpalis I, Boutzios G, Kaltsas GA
Biomed Res Int 2017;2017:9856140. Epub 2017 Nov 19 doi: 10.1155/2017/9856140. PMID: 29349087Free PMC Article
Management of neuroendocrine tumors.
Chung C
Am J Health Syst Pharm 2016 Nov 1;73(21):1729-1744. doi: 10.2146/ajhp150373. PMID: 27769969
Pancreatic neoplasm in 2011: an update.
Saif MW
JOP 2011 Jul 8;12(4):316-21. PMID: 21737886

Prognosis

ASO Practice Guidelines Series: Surgical Management of Gastrointestinal (Midgut) Neuroendocrine Neoplasms.
Hallet J, Clarke CN
Ann Surg Oncol 2024 Mar;31(3):1704-1713. Epub 2024 Jan 2 doi: 10.1245/s10434-023-14802-8. PMID: 38167813
(177)Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators
Lancet Oncol 2021 Dec;22(12):1752-1763. Epub 2021 Nov 15 doi: 10.1016/S1470-2045(21)00572-6. PMID: 34793718
The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets.
van Riet J, van de Werken HJG, Cuppen E, Eskens FALM, Tesselaar M, van Veenendaal LM, Klümpen HJ, Dercksen MW, Valk GD, Lolkema MP, Sleijfer S, Mostert B
Nat Commun 2021 Jul 29;12(1):4612. doi: 10.1038/s41467-021-24812-3. PMID: 34326338Free PMC Article
Pancreatic neoplasm in 2011: an update.
Saif MW
JOP 2011 Jul 8;12(4):316-21. PMID: 21737886
Surgery for midgut carcinoid.
Sutton R, Doran HE, Williams EM, Vora J, Vinjamuri S, Evans J, Campbell F, Raraty MG, Ghaneh P, Hartley M, Poston GJ, Neoptolemos JP
Endocr Relat Cancer 2003 Dec;10(4):469-81. doi: 10.1677/erc.0.0100469. PMID: 14713260

Clinical prediction guides

(177)Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators
Lancet Oncol 2021 Dec;22(12):1752-1763. Epub 2021 Nov 15 doi: 10.1016/S1470-2045(21)00572-6. PMID: 34793718
Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results.
Pavel M, Ćwikła JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Capdevila J, Panzuto F, Truong Thanh XM, Houchard A, Ruszniewski P
Eur J Cancer 2021 Nov;157:403-414. Epub 2021 Sep 28 doi: 10.1016/j.ejca.2021.06.056. PMID: 34597974
The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets.
van Riet J, van de Werken HJG, Cuppen E, Eskens FALM, Tesselaar M, van Veenendaal LM, Klümpen HJ, Dercksen MW, Valk GD, Lolkema MP, Sleijfer S, Mostert B
Nat Commun 2021 Jul 29;12(1):4612. doi: 10.1038/s41467-021-24812-3. PMID: 34326338Free PMC Article
Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology.
Javle M, Hsueh CT
J Hematol Oncol 2010 Mar 23;3:11. doi: 10.1186/1756-8722-3-11. PMID: 20331897Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...